Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: European Journal of Nuclear Medicine and Molecular Imaging, 52, S. 970-978
- Event
-
Veröffentlichung
- (where)
-
Augsburg
- (who)
-
Universität Augsburg
- (when)
-
2025
- Event
-
Veröffentlichung
- (where)
-
Berlin
- (who)
-
Springer Science and Business Media LLC
- (when)
-
2025
- Creator
-
Gäble, Alexander
Dierks, Alexander
Rinscheid, Andreas
Patt, Marianne
Wienand, Georgine
Pfob, Christian H.
Kircher, Malte
Fukushima, Kazuhito
Nikolić, Ana Antić
Enke, Johanna S.
Janzen, Tilman
Steinestel, Julie
Kempter, Hildegard
Trepel, Martin
Weckermann, Dorothea
Lapa, Constantin Frederik Victor
Bundschuh, Ralph A.
- DOI
-
10.1007/s00259-024-06959-5
- URN
-
urn:nbn:de:bvb:384-opus4-1171269
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gäble, Alexander
- Dierks, Alexander
- Rinscheid, Andreas
- Patt, Marianne
- Wienand, Georgine
- Pfob, Christian H.
- Kircher, Malte
- Fukushima, Kazuhito
- Nikolić, Ana Antić
- Enke, Johanna S.
- Janzen, Tilman
- Steinestel, Julie
- Kempter, Hildegard
- Trepel, Martin
- Weckermann, Dorothea
- Lapa, Constantin Frederik Victor
- Bundschuh, Ralph A.
- Universität Augsburg
- Springer Science and Business Media LLC
Time of origin
- 2025
Other Objects (12)
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Improved quality control of [177Lu]Lu-PSMA I&T
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
First safety and efficacy data with the radiohybrid 177Lu-rhPSMA-10.1 for the treatment of metastatic prostate cancer
EP-0565 Safety and efficacy of [177Lu]Lu-rhPSMA-10.1 re-challenge therapy in progressive mCRPC after [177Lu] Lu-PSMA I&T therapy: preliminary results [Abstract]
[177Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Improved quality control of [177Lu]Lu-PSMA I&T
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
First safety and efficacy data with the radiohybrid 177Lu-rhPSMA-10.1 for the treatment of metastatic prostate cancer
EP-0565 Safety and efficacy of [177Lu]Lu-rhPSMA-10.1 re-challenge therapy in progressive mCRPC after [177Lu] Lu-PSMA I&T therapy: preliminary results [Abstract]
[177Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Improved quality control of [177Lu]Lu-PSMA I&T
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
First safety and efficacy data with the radiohybrid 177Lu-rhPSMA-10.1 for the treatment of metastatic prostate cancer
EP-0565 Safety and efficacy of [177Lu]Lu-rhPSMA-10.1 re-challenge therapy in progressive mCRPC after [177Lu] Lu-PSMA I&T therapy: preliminary results [Abstract]